Activation of the Retinoid X Receptor Suppresses Appetite in the Rat

Endocrinology

Volumn 145, Issue 2, 2004, Pages 565-573

  Ogilvie, Kathleen M ^a,c   Saladin, Régis ^a,d   Nagy, Tim R ^b   Urcan, Mary S ^a   Heyman, Richard A ^a,e   Leibowitz, Mark D ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c PFIZER INC   (United States)

^d CAREX SA   (France)

^e EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; LG 268; RETINOID X RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APPETITE; ARTICLE; AVERSIVE BEHAVIOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; ENERGY BALANCE; FEMALE; FOOD INTAKE; INSULIN RESISTANCE; LIPID METABOLISM; MALAISE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SATIETY; SUBCUTANEOUS FAT; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; APPETITE REGULATION; BRAIN; EATING; ENERGY METABOLISM; FEMALE; FOOD; HOMEOSTASIS; INJECTIONS, INTRAVENTRICULAR; INSULIN; LIPIDS; OBESITY; ORGANIC CHEMICALS; RATS; RATS, ZUCKER; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; SATIATION; TRANSCRIPTION FACTORS; TRIGLYCERIDES; WEIGHT GAIN;

EID: 0842334616     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0907     Document Type: Article

References (49)

1. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870
2. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841-850
3. Emilsson V, O'Dowd J, Wang S, Liu YL, Sennitt M, Heyman R, Cawthorne MA 2000 The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49:1610-1615
4. Liu YL, Sennitt MV, Hislop DC, Crombie DL, Heyman RA, Cawthorne MA 2000 Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obes Relat Metab Disord 24:997-1004
5. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE, Suto CM, Davies JA, Heyman RA, Nadzan AM 1995 Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 38:3146-3155
6. Lala DS, Mukherjee R, Schulman IG, Koch SS, Dardashti LJ, Nadzan AM, Croston GE, Evans RM, Heyman RA 1996 Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383:450-453
7. Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD 2002 Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 143:2880-2885
8. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL 1994 [[ω-(Heterocyclylamino)alkoxy] benzyl]-2, 4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985
9. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW 1994 A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210
10. Wagstaff AJ, Goa KL 2002 Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837
11. Dobush GR, Ankney CD, Krementz DG 1985 The effect of apparatus, extraction time, and solvent type on lipid extractions of snow geese. Can J Zool 63:1917-1920
12. Ogilvie KM, Rivier C 1996 Gender difference in alcohol-evoked hypothalamic-pituitary-adrenal activity in the rat: ontogeny and role of neonatal steroids. Alcohol Clin Exp Res 20:255-261
13. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR 1999 The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic β-cell dysfunction. Diabetologia 42:545-554
14. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD 1996 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195
15. Walker AB, Chattington PD, Buckingham RE, Williams G 1999 The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1453
16. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P 1997 Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399
17. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW 1998 Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 83:3169-3176
18. Standeven AM, Thacher SM, Yuan YD, Escobar M, Vuligonda V, Beard RL, Chandraratna RA 2001 Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents. Biochem Pharmacol 62:1501-1509
19. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J 2001 Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol Pharmacol 59:170-176
20. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J 2001 Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 98:2610-2615
21. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell Jr RP 1997 Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15:790-795
22. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ 1999 A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664
23. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340:1075-1079
24. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC 1996 Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094
25. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T 1998 Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361
26. Zetterstrom RH, Lindqvist E, Mata de Urquiza A, Tomac A, Eriksson U, Perlmann T, Olson L 1999 Role of retinoids in the CNS: differential expression of retinoid binding proteins and receptors and evidence for presence of retinoic acid. Eur J Neurosci 11:407-416
27. Krezel W, Kastner P, Chambon P 1999 Differential expression of retinoid receptors in the adult mouse central nervous system. Neuroscience 89:1291-1300
28. Barzilai N, Banerjee S, Hawkins M, Chen W, Rossetti L 1998 Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 101:1353-1361
29. Holness MJ, Howard RM, Bentley J, Sugden MC 1992 Skeletal muscle glucose utilization in response to a decreased meal frequency. Biochem Soc Trans 20:196S
30. Turnbull AV, Rivier CL 1998 Intracerebroventricular passive immunization. I. The effect of intracerebroventricular administration of an antiserum to tumor necrosis factor-α on the plasma adrenocorticotropin response to lipopolysaccharide in rats. Endocrinology 139:119-127
31. Maness LM, Kastin AJ, Farrell CL, Banks WA 1998 Fate of leptin after intracerebroventricular injection into the mouse brain. Endocrinology 139:4556-4562
32. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, Kadowaki T 2001 Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013
33. Zetterstrom RH, Solomin L, Mitsiadis T, Olson L, Perlmann T 1996 Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol Endocrinol 10:1656-1666
34. Ross AW, Webster CA, Mercer JA, Moar KM, Ebling FA, Schuhler S, Barrett P, Morgan PJ 2004 Photoperiodic regulation of hypothalamic retinoid signaling: association of retinoid X receptor γ with bodyweight. Endocrinology 145:13-20
35. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ 2001 Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 98:4652-4657
36. Pelleymounter MA, Cullen MJ, Wellman CL 1995 Characteristics of BDNF-induced weight loss. Exp Neurol 131:229-238
37. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C 2002 Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8:825-830
38. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM 1997 Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 94:8878-8883
39. Jackson HC, Cheetham SC, Jones RB, Forni JJ, Pleasance IM, Slater NA, Heal DJ 1997 Effect of chronic administration of sibutramine and its withdrawal on body weight and food intake in obese Zucker rats. Int J Obes 21:S56
40. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SF 2002 Preservation of pancreatic ̂-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803
41. Lee CH, Olson F, Evans RM 2003 Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207
42. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS 2001 The rexinoid LG100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. Mol Endocrinol 15:1360-1369
43. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S 2002 Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists. Diabetes 51:718-723
44. Johnson PR, Zucker LM, Cruce JA, Hirsch J 1971 Cellularity of adipose depots in the genetically obese Zucker rat. J Lipid Res 12:706-714
45. Kelly IE, Han TS, Walsh K, Lean ME 1999 Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293
46. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y 1999 Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912
47. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y 2003 PPAR̄ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52:291-299
48. Pijl H, Meinders AE 1996 Body weight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 14:329-342
49. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ 2001 Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 59:765-773